Verified 2026-05-06 (full PDF pass). Strait & Lakatta 2012 read via PMC full-text; three quantitative claims corrected (LV wall thickness %, SAN cell absolute count, aortic sclerosis prevalence — all removed/re-qualified as not present in source). Go 2001 abstract confirmed via PubMed; AF age-bracket corrected. Bergmann 2009 abstract confirmed. Lakatta & Levy 2003 remains unverified (closed-access). See verified-scope for full details.

Heart

The heart is the four-chambered muscular pump that drives systemic and pulmonary circulation. It is composed of three tissue layers (myocardium, endocardium, epicardium), four valves (mitral, tricuspid, aortic, pulmonary), the cardiac conduction system, and the coronary vasculature — all enclosed in the fibrous pericardial sac. Aging degrades virtually every functional compartment of the heart: the myocardium hypertrophies and stiffens, the conduction system loses pacemaker cells, valvular leaflets calcify, and coronary arteries accumulate atherosclerotic plaque ¹².

The heart is one of the most aging-sensitive organs in the body. Cardiovascular disease is the leading cause of death in adults over 65 in high-income countries, and the underlying cellular mechanisms (cardiomyocyte senescence, fibrosis, impaired proteostasis, mitochondrial dysfunction) are directly trackable to the Hallmarks of Aging. Quantitative mechanistic detail is concentrated on the atomic tissue page myocardium (verified); this page is a synthesis MOC at the organ level.

Anatomy at a glance

The heart weighs approximately 250–350 g in adult humans and contracts ~100,000 times per day. Its four chambers — right atrium (RA), right ventricle (RV), left atrium (LA), left ventricle (LV) — are separated by the interatrial and interventricular septa and gated by four valves:

Valve	Location	Function
Tricuspid	RA → RV	Prevents right-sided regurgitation
Pulmonary	RV → pulmonary artery	Prevents pulmonic regurgitation
Mitral	LA → LV	Prevents left-sided regurgitation
Aortic	LV → aorta	Most susceptible to age-related calcification

Conduction system: The sinoatrial node (SAN, right atrial wall near the superior vena cava) generates the primary electrical impulse. Signal propagates through the atria to the atrioventricular node (AVN), then via the Bundle of His, left/right bundle branches, and Purkinje fiber network to the ventricular myocardium.

Coronary circulation: The left anterior descending (LAD), left circumflex (LCx), and right coronary artery (RCA) supply the myocardium. Obstruction of these vessels by atherosclerosis causes myocardial infarction (MI), the dominant acute cardiac catastrophe in aging humans.

Pericardium: A fibrous sac surrounding the heart; becomes less compliant with age and can accumulate effusion in inflammatory states. Not a primary site of aging change but relevant context.

Tissue layers

Layer	Description	Aging-relevant changes
Epicardium	Outer serous membrane; contains autonomic nerve terminals and coronary vessels	Epicardial fat (pericardial adipose tissue) accumulates with age; a source of paracrine inflammatory signals
Myocardium	Middle muscular layer; bulk of cardiac mass; cardiomyocytes + fibroblasts + ECM	Concentric hypertrophy, interstitial fibrosis, mitochondrial dysfunction, cardiomyocyte senescence — see myocardium (verified)
Endocardium	Inner endothelial lining of chambers and valves	Endothelial senescence; valvular leaflet calcification (especially aortic)

For mechanistic, cellular, and molecular detail on the myocardium, see myocardium (verified). This organ-level page synthesizes and links; it does not duplicate claims already sourced there.

Aging phenotypes at the organ level

Left ventricular concentric hypertrophy and diastolic dysfunction

The dominant structural change of cardiac aging is left ventricular concentric hypertrophy — increased LV wall thickness relative to chamber volume — driven by cardiomyocyte hypertrophy (not hyperplasia) and interstitial fibrosis. Wall stiffening impairs diastolic filling, producing diastolic dysfunction and eventually heart failure with preserved ejection fraction (HFpEF), the predominant cardiac syndrome in adults over 65. With healthy aging, LV wall thickness increases asymmetrically (interventricular septum more than the free wall), but total LV mass does not increase — in men it actually decreases; in women it is unchanged ¹. unsourced — a specific percentage increase in septal or total wall thickness between ages 25 and 80 is not stated in ¹; if a precise figure (e.g., ~25–30%) is needed, a primary echocardiographic or BLSA imaging study (e.g., Gerstenblith 1977, Levy 1988, or Kitzman 2001 BLSA data) should be cited.

Key consequences:

Impaired LV relaxation (prolonged isovolumic relaxation time on echocardiography)
Elevated filling pressures (elevated E/e’ ratio)
Exercise intolerance despite preserved resting EF (~55–65%)
Predisposition to atrial fibrillation (elevated LA pressure → LA dilation)

See myocardium (verified) for cellular mechanism (cardiomyocyte SASP → fibroblast activation → collagen deposition) and cardiac-fibrosis for structural detail.

Sinoatrial node aging (pacemaker cell loss)

The SAN contains a specialized population of pacemaker cardiomyocytes (If-channel expressing) that decline in number with age due to apoptosis, fibrosis, and replacement by adipose and fibrous tissue ¹. A pronounced decline in pacemaker cell number occurs after age 60; by age 75 fewer than 10% of the pacemaker cells present in young adults remain ¹. unsourced — the absolute SAN pacemaker cell count in healthy young adults (~10,000–20,000 cells is a commonly cited estimate in secondary literature; not stated in ¹; primary source is Shiraishi et al. 1992 histomorphometric study, not archive-confirmed). Consequences of SAN aging include:

Resting heart rate reduction: maximum achievable heart rate declines with age; SAN cell loss limits chronotropic reserve. The widely-cited formula max HR ≈ 220 − age implies ~1 beat/min per year, but ¹ does not state this exact rate — it notes maximal heart rate is lower in older individuals and is not offset by physical conditioning.
Sick sinus syndrome (SSS): symptomatic SAN dysfunction — bradycardia, chronotropic incompetence, sinus pauses. Prevalence rises sharply >65 years; SSS is the most common indication for pacemaker implantation in older adults.
Increased AF susceptibility: SAN fibrosis creates a substrate for re-entrant arrhythmia. SAN remodeling reduces the anatomic barrier between the sinus node and the right atrium, facilitating aberrant impulse formation.

needs-replication — quantitative SAN cell-number decline with age in human hearts has not been systematically replicated since the original histomorphometric studies (Shiraishi et al. 1992; not archive-confirmed; see unsourced below). ¹ reviews the literature but the underlying primary data needs direct verification.

Atrial fibrillation

AF is the most common sustained cardiac arrhythmia, and age is its dominant risk factor. Prevalence in US adults ³:

Age <55 years: ~0.1% (abstract-confirmed)
Age 80+: ~9.0% (abstract-confirmed)
Overall diagnosed prevalence: ~2.3 million US adults (2001 estimate; substantially higher by 2020s)

Note: The intermediate age-band figure (~2.3% at age 60–69) is commonly cited alongside this paper but is not stated in the Go 2001 abstract; it may appear in full-text Table 1, which is behind a paywall (#gap/no-fulltext-access for this specific figure).

AF arises from structural (LA dilation, fibrosis), electrophysiological (altered ion channel expression, SAN remodeling), and autonomic (diminished parasympathetic tone) changes that collectively create a substrate for re-entry and ectopic impulse generation. Age-related chronic-inflammation and cellular-senescence in atrial myocytes and fibroblasts contribute directly to the fibrotic substrate.

needs-human-replication — whether senolytic clearance of senescent atrial cells reduces incident AF has not been tested in humans as of 2026-05-06. atrial-fibrillation (implicit stub).

Aortic valve calcification (sclerosis → stenosis)

The aortic valve undergoes progressive calcification with age, driven by:

Lipid accumulation and oxidative stress in leaflet tissue (mechanism overlaps with atherosclerosis)
Osteoblast-like differentiation of valve interstitial cells (regulated by RUNX2 and BMP signaling)
Chronic low-grade inflammation

Cross-link — cardiac vs venous valves: cardiac valves share a developmental program (NFATc1/calcineurin, Notch, BMP, EndMT) with the venous valves, but diverge in failure mode — cardiac valves calcify (osteogenic VIC transdifferentiation) or degenerate myxomatously, whereas venous valves fail by reflux (leaflet stretch + wall dilation). Notably the venous/lymphatic valve transcription factor PROX1 also protects against myxomatous mitral degeneration. See veins § Comparison to cardiac valves.

Aortic sclerosis (calcification without hemodynamic obstruction) is present in ~25% of adults aged 65–74 and ~50% of adults aged ≥75. unsourced — these prevalence figures are widely cited in clinical cardiology (original source: Otto CM et al. 1999 NEJM or Stewart BF et al. 1997 JACC — not verified in archive) but are NOT stated in ¹, which discusses aortic valve calcification mechanistically without providing prevalence statistics. Citation removed from prevalence claim; a primary epidemiologic study must be cited here. Sclerosis progresses to aortic stenosis (hemodynamically significant obstruction) at ~2%/year unsourced; severe AS (valve area <1 cm²) has a 50% 2-year mortality without intervention unsourced. Transcatheter aortic valve replacement (TAVR) is the dominant intervention in high-surgical-risk patients >75.

Coronary artery disease (link to atherosclerosis)

Age is the dominant non-modifiable risk factor for coronary artery disease. Coronary atherosclerosis — intimal plaque accumulation driven by endothelial dysfunction, LDL oxidation, macrophage foam cell formation, and chronic inflammation — is mechanistically upstream of myocardial infarction. Detailed mechanism on atherosclerosis (drafted). The cardiac consequence is:

Acute MI (plaque rupture + thrombosis) → irreversible myocardial scar → LV remodeling
Chronic ischemia → hibernating myocardium → heart failure with reduced EF (HFrEF)

Regenerative capacity

The heart has negligible cardiomyocyte regenerative capacity in adult humans. Bergmann et al. 2009 (radiocarbon ¹⁴C dating of cardiac DNA) estimated cardiomyocyte renewal at ~1%/year at age 25, declining to ~0.45%/year at age 75 ⁴. The 2015 follow-up (Bergmann et al. 2015, n=51 hearts) confirmed that total cardiomyocyte number does not change from birth to old age (R=0.01, p=0.96) and revised the age-75 renewal rate downward to <0.3%/year — these data are sourced and verified on myocardium (verified).

Practical implication: myocardial infarction (death of >1 billion cardiomyocytes in a typical MI) leaves a permanent fibrotic scar. No therapeutic approach has yet demonstrated meaningful cardiomyocyte regeneration in large mammals; promising rodent strategies (Hippo/YAP, ERBB2 transient overexpression, miRNA-199a/590) have not translated to humans.

needs-human-replication — CM regeneration strategies remain preclinical; no phase 3 human trial has demonstrated functional cardiac regeneration as of 2026-05-06. Note: the Bergmann 2015 downward revision of the age-75 renewal rate (to <0.3%/year, n=51 hearts; sourced on myocardium verified) supersedes the 2009 estimate of ~0.45%/year cited in ⁴ — any downstream page relying on the 2009 figure for this age-75 rate should prefer the 2015 value.

Cardiac aging biomarkers

These circulating markers reflect organ-level cardiac stress and are elevated in aging and disease:

Biomarker	Source	What it reflects	Notes
NT-proBNP (N-terminal pro-B-type natriuretic peptide)	Released by stressed cardiomyocytes	LV wall stress, volume overload, HF severity	Clinical standard for HF diagnosis; rises with age even in the absence of overt HF; >125 pg/mL diagnostic threshold for HF in most guidelines
hs-cTnT (high-sensitivity cardiac troponin T)	Released from damaged cardiomyocytes	Subclinical myocardial injury	Chronically elevated hs-cTnT predicts adverse cardiovascular outcomes independently of clinical HF diagnosis; detectable in most older adults at trace levels
GDF-15 (growth differentiation factor 15)	Myocardium + other tissues under stress	Mitochondrial stress, inflammation, cardiac aging	Part of cardiomyocyte SASP in aged mice (Tgfb2/Gdf15/Edn3 — Anderson 2019; see myocardium for source); elevated GDF-15 predicts all-cause and cardiovascular mortality in older adults unsourced

unsourced — NT-proBNP age-trajectory, hs-cTnT chronic-elevation claims, and GDF-15 human mortality-prediction claim are widely cited in clinical cardiology but specific primary citations are not attached here; see cardiovascular-aging (drafted) for sourced clinical discussion. Note: the GDF-15 SASP role (Anderson 2019, mouse data) is verified on myocardium; the claim that elevated circulating GDF-15 predicts mortality in older humans is a separate clinical claim requiring its own human-cohort citation.

Hallmark connections

Hallmark	Organ-level mechanism
cellular-senescence	Cardiomyocyte senescence (oxidative telomere damage, non-canonical SASP); CPC senescence (>50% p16+ in >70yr); SAN cell loss with fibrotic replacement — see myocardium for sources
mitochondrial-dysfunction	Cardiomyocyte high OXPHOS dependence (~90% of ATP from mitochondria); mtDNA deletion accumulation; impaired mitophagy; direct consequence: diastolic dysfunction and HFpEF
chronic-inflammation	SASP-driven fibroblast activation; atrial fibrosis (AF substrate); epicardial adipose paracrine signaling; macrophage inflammaging in coronary vessels
stem-cell-exhaustion	CPC functional exhaustion; near-zero net CM regeneration; SAN pacemaker cell loss
loss-of-proteostasis	Protein aggregate accumulation in post-mitotic CMs (amyloid, cross-linked collagen); UPS and autophagy decline; chaperone capacity reduction

Aging-protective interventions (organ level)

Intervention	Mechanism	Evidence level
Aerobic exercise	Preserves mitochondrial density; reduces resting HR; improves LV compliance; reduces HFpEF risk; maintains VO₂max	Strong (observational + RCT; VO₂max preservation most protective)
SGLT2 inhibitors	Reduce myocardial fibrosis + inflammation; ketone utilization by cardiomyocytes; HFpEF mortality benefit	Strong human RCT (empagliflozin EMPEROR-Preserved; dapagliflozin DELIVER)
GDMT (ACEi/ARB/ARNi, β-blockers, MRA)	Reduce afterload + neurohormonal activation; prevent post-MI remodeling	Strong human RCT (primarily HFrEF; ARNi sacubitril/valsartan PARADIGM-HF)
Senolytics (navitoclax, D+Q)	Clear senescent CMs and CPCs; reduce fibrosis and hypertrophy in mice	Preclinical only; no completed human cardiac-specific senolytic trial needs-human-replication
mTOR inhibition (rapamycin/everolimus)	Restore autophagy/mitophagy; extend mouse lifespan with cardiac benefit	Preclinical well-supported; PEARL 2025 human trial showed no improvement in aortic stiffness (primary endpoint non-significant); see rapamycin

Limitations and gaps

#gap/needs-human-replication — senolytics for cardiac aging (all data in mice; no completed human trial targeting cardiac senescent cells); CM regeneration strategies; AF senolytic prevention
#gap/needs-replication — SAN pacemaker cell-number quantification across human ages (original Shiraishi 1992 histomorphometry; no large independent replication confirmed in archive)
#gap/unsourced — NT-proBNP and hs-cTnT age-trajectory claims; GDF-15 human mortality-prediction claim (mouse SASP role verified on myocardium; circulating GDF-15 mortality prediction in older humans needs human-cohort citation); SAN cell-count decline needs primary citation; epicardial adipose paracrine aging signals
#gap/no-mechanism — why aortic valve calcification is more prominent than mitral in aging (mechanical strain hypothesis vs biochemical predisposition — not definitively resolved)
#stub — atrial-fibrillation, cardiovascular-system, vascular-smooth-muscle-cells are implicit stubs; cardiac-fibroblasts and endothelial-cells pages need seeding for full cross-link integrity

Cross-references

myocardium (verified) — primary atomic page for cardiac muscle tissue; all quantitative CM turnover, SASP, and CPC data sourced and verified there
cardiomyocytes (verified-partial) — primary atomic page for CM cell biology
cardiac-fibrosis (verified-partial) — structural consequence; fibroblast activation and interstitial fibrosis mechanisms
heart-failure (drafted) — clinical outcome page; HFpEF and HFrEF; diagnostic criteria and outcomes
cardiovascular-aging (drafted) — system-level MOC; vascular + cardiac combined overview
atherosclerosis (drafted) — coronary artery disease mechanism; upstream of MI
atrial-fibrillation (implicit stub) — AF at the atomic level; to be seeded
cardiovascular-system (implicit stub) — parent system MOC
vascular-smooth-muscle-cells (implicit stub) — coronary and aortic medial layer cells
cardiac-fibroblasts (planned) — fibrosis effector cells
cellular-senescence — hallmark MOC; CM + CPC + endothelial senescence
mitochondrial-dysfunction — hallmark MOC; cardiomyocytes as paradigm case
chronic-inflammation — hallmark MOC; SASP + inflammaging in cardiac context
stem-cell-exhaustion — hallmark MOC; CPC functional exhaustion
loss-of-proteostasis — hallmark MOC; CM protein aggregate accumulation
mtor — mTOR hyperactivation suppresses CM autophagy
ampk — AMPK decline worsens cardiac aging; heart-specific data on myocardium
rapamycin — PEARL 2025 human trial context

Footnotes

doi:10.1016/j.hfc.2011.08.011 · Strait JB, Lakatta EG · “Aging-Associated Cardiovascular Changes and Their Relationship to Heart Failure” · Heart Fail Clin 8(1):143–164 · 2012 · review · 711 citations (OA; read via PMC full-text XML, PMC3223374, 2026-05-06). Key verified findings: SAN pacemaker cells decline “pronounced” after age 60, with <10% remaining by age 75 (relative to young-adult count); LV mass does not increase with aging in healthy normotensive adults (men decrease, women unchanged); wall thickening is asymmetric and septal. Aortic sclerosis prevalence and LV wall thickness % figures (~25-30%) are NOT in this paper. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹
doi:10.1161/01.cir.0000048892.83521.58 · Lakatta EG, Levy D · “Arterial and Cardiac Aging: Major Shareholders in Cardiovascular Disease Enterprises” · Circulation 107(2):139–146 · 2003 · review · 2161 citations (archive confirmed; not OA — PDF not locally downloaded) ↩
doi:10.1001/jama.285.18.2370 · Go AS, Hylek EM, Phillips KA et al. · “Prevalence of Diagnosed Atrial Fibrillation in Adults” · JAMA 285(18):2370–2375 · 2001 · observational · model: Kaiser Permanente health plan members (ATRIA Study); total health-plan population 1.89 million; 17,974 AF cases identified (n=17,974 cases, NOT 17,974 total subjects) · Abstract confirmed (PubMed PMID 11343485, 2026-05-06): AF prevalence 0.1% for adults <55 years; 9.0% for adults ≥80 years; total prevalence 0.95% (95% CI 0.94–0.96%); estimated 2.3 million Americans with diagnosed AF. Note: the 2.3% figure at age 60–69 is NOT stated in the abstract and may appear in full-text Table 1 (not verified — paper is closed-access) no-fulltext-access ↩
doi:10.1126/science.1164680 · Bergmann O, Bhardwaj RD, Bernard S et al. · “Evidence for Cardiomyocyte Renewal in Humans” · Science 324(5923):98–102 · 2009 · observational · model: post-mortem human hearts; ¹⁴C radiocarbon dating of cardiac DNA · n not stated in abstract (DOI lookup failed; PMC2991140 exists but full-text body n not extractable from partial fetch) no-fulltext-access for exact n · Abstract confirmed (PubMed PMID 19342590, 2026-05-06): ~1%/yr CM renewal at age 25 declining to ~0.45%/yr at 75; fewer than 50% of CMs exchanged across a normal lifespan (2009 estimate; superseded by Bergmann 2015 which revised age-75 rate to <0.3%/yr using n=51 hearts — see myocardium verified); 3101 citations ↩ ↩²

🧬 Aging Wiki

Explorer

heart